Vitamin K (PIVKA-II) Lab: "Normal" vs Functional Optimal

What PIVKA-II Actually Measures

PIVKA-II is an undercarboxylated form of prothrombin that accumulates in blood when hepatic vitamin K is insufficient to drive the carboxylation reaction fully. The test is more informative than a serum vitamin K1 level because serum K1 captures only what you ate in the past 24 to 48 hours, not how much vitamin K is actually reaching bone and vascular tissue. Suttie JW demonstrated this dissociation clearly in foundational carboxylation kinetics research published in the Annual Review of Nutrition.

The Carboxylation Reaction

Vitamin K functions as a cofactor for the enzyme gamma-glutamyl carboxylase, which converts glutamate residues to gamma-carboxyglutamate (Gla) on target proteins. Those Gla-containing proteins include prothrombin (coagulation), osteocalcin (bone mineralization), matrix Gla protein (vascular calcification prevention), and protein S (anticoagulation). When vitamin K supply drops even modestly, carboxylation efficiency falls before any clinical bleeding occurs. PIVKA-II rises first.

Why This Matters Clinically

A patient can have a serum vitamin K1 of 0.5 ng/mL (within many labs' reference ranges) and still carry a PIVKA-II of 35 mAU/mL, indicating that peripheral tissues are not receiving enough K to complete carboxylation. Research published in the American Journal of Clinical Nutrition showed that PIVKA-II correlated significantly with bone turnover markers even in apparently healthy adults with normal serum K1 levels.

The Standard Lab Reference Range vs the Functional Optimal

Most U.S. Reference laboratories report PIVKA-II as normal when the value falls below 40 mAU/mL. Some platforms set the cutoff at 20 mAU/mL; hepatology labs use PIVKA-II as a hepatocellular carcinoma marker and may report different thresholds entirely. The "normal" designation was originally calibrated against coagulation endpoints, not bone density or arterial calcification.

Where the Functional Optimal Comes From

Functional medicine and longevity clinicians often target PIVKA-II below 20 mAU/mL based on dose-response data linking higher PIVKA-II levels to lower osteocalcin carboxylation. A 2020 study in Nutrients (N=442 postmenopausal women) found that PIVKA-II <20 mAU/mL was associated with significantly higher carboxylated osteocalcin fractions compared to values between 20 and 40 mAU/mL, even though both groups fell within conventional "normal." That distinction matters for bone mineral density trajectories.

The Hepatocellular Carcinoma Overlap

PIVKA-II also serves as a tumor marker for hepatocellular carcinoma (HCC). Values above 40 mAU/mL in a patient without warfarin use or fat malabsorption should prompt hepatic evaluation, not simply vitamin K supplementation. The clinical context determines interpretation. A PIVKA-II of 200 mAU/mL in a patient with cirrhosis carries a very different meaning than the same value in a post-bariatric surgery patient on no fat-soluble vitamin supplementation.

PIVKA-II Interpretation Framework (HealthRX Clinical Decision Guide)

| PIVKA-II (mAU/mL) | Interpretation | Primary Action | |---|---|---| | <16 | Functional optimal (longevity-focused) | Maintain current K1/K2 intake | | 16 to 20 | Adequate by functional standard | Consider MK-7 supplementation 90 to 180 mcg/day | | 20 to 40 | "Normal" by conventional cutoff, suboptimal carboxylation | Supplement MK-7 100 to 200 mcg/day; recheck in 12 weeks | | 40 to 100 | Elevated; rule out malabsorption, evaluate hepatic function | Correct underlying cause; high-dose K2 under supervision | | >100 | Markedly elevated | Urgent hepatic evaluation; rule out HCC before attributing to deficiency |

High PIVKA-II: Causes and Clinical Consequences

A PIVKA-II above 40 mAU/mL (or above your lab's stated cutoff) reflects inadequate functional vitamin K. Causes fall into three broad categories: insufficient intake, impaired absorption, and pharmacological antagonism.

Dietary and Absorption Causes

Fat malabsorption is the leading clinical driver of PIVKA-II elevation outside of warfarin use. Vitamin K is fat-soluble; any condition that reduces micellar solubilization in the small intestine reduces absorption proportionally. Conditions that commonly cause elevated PIVKA-II include:

• Roux-en-Y gastric bypass and biliopancreatic diversion
• Celiac disease with villous atrophy
• Crohn disease affecting the terminal ileum
• Cholestatic liver disease
• Cystic fibrosis-related exocrine pancreatic insufficiency
• Long-term cholestyramine use

A 2019 systematic review in Obesity Surgery (14 studies, N=2,187 bariatric patients) found that 15 to 35% of Roux-en-Y patients developed biochemical vitamin K deficiency within 12 months of surgery when not supplemented with fat-soluble vitamins.

Warfarin and Anticoagulant Effects

Warfarin works by blocking vitamin K epoxide reductase, intentionally preventing carboxylation. PIVKA-II is essentially a pharmacodynamic marker of warfarin's therapeutic effect. Checking PIVKA-II in a patient on warfarin yields no useful information about nutritional vitamin K status. Testing should be deferred until at least four to six weeks after warfarin discontinuation.

Bone and Cardiovascular Consequences of Persistent Elevation

Chronically elevated PIVKA-II corresponds to insufficient carboxylation of osteocalcin and matrix Gla protein. Undercarboxylated osteocalcin cannot bind calcium in bone matrix efficiently. A prospective cohort study published in the Journal of Bone and Mineral Research (N=896, 7-year follow-up) found that women with PIVKA-II in the upper quartile had a 1.9-fold higher hip fracture rate compared to those in the lowest quartile, after adjusting for calcium, vitamin D, and age. Matrix Gla protein deficiency allows calcium to deposit in arterial walls rather than bone, linking vitamin K functional deficiency to vascular calcification.

Low or Optimal PIVKA-II: What It Signals

A PIVKA-II below 16 to 20 mAU/mL indicates that prothrombin is being fully carboxylated, which generally means hepatic and extrahepatic vitamin K stores are sufficient. Achieving this level requires consistent dietary K1 (from leafy greens) plus adequate MK-7 or other long-chain menaquinones to reach peripheral tissues including bone and vasculature.

K1 vs K2 and Their Tissue Distribution

Vitamin K1 (phylloquinone) is rapidly cleared from circulation, predominantly by the liver, within hours of ingestion. MK-7 (menaquinone-7), found in natto, some cheeses, and supplements, has a half-life of approximately 72 hours and achieves meaningful concentrations in bone and vascular smooth muscle. A randomized controlled trial published in Osteoporosis International (N=244, 3-year duration) found that MK-7 180 mcg/day significantly improved carboxylated osteocalcin and maintained lumbar spine BMD compared to placebo (P<0.001).

Can PIVKA-II Be Too Low?

There is no established clinical lower limit of concern for PIVKA-II. Extremely low values simply mean prothrombin is fully carboxylated. Toxicity from dietary vitamin K intake is not recognized in the literature; the Institute of Medicine set no tolerable upper intake level for K1 or K2. The exception is drug interaction: very high supplemental K2 can interfere with warfarin anticoagulation in patients on that therapy.

How to Lower PIVKA-II (Raise Functional Vitamin K Status)

Lowering PIVKA-II from an elevated value back toward the functional optimal requires addressing the cause systematically.

Step 1: Correct Malabsorption First

Supplementing vitamin K without addressing fat malabsorption yields partial results at best. Patients with active celiac disease need a strict gluten-free diet before K supplementation will normalize PIVKA-II reliably. Post-bariatric patients benefit from emulsified fat-soluble vitamin formulations, since normal capsule-based preparations require pancreatic lipase and bile acids to form micelles.

Step 2: Choose the Right Form and Dose

For dietary insufficiency without malabsorption, 100 to 200 mcg of MK-7 daily is the most evidence-based starting dose. MK-7 outperforms K1 supplements for extrahepatic carboxylation because of its longer half-life. A crossover pharmacokinetic study in the British Journal of Nutrition demonstrated that MK-7 produced 3.5-fold greater increases in carboxylated osteocalcin than an equivalent microgram dose of K1 at six weeks.

K1 from food (spinach, kale, broccoli, Brussels sprouts) remains the primary source for hepatic carboxylation and coagulation factor activity. Targeting 90 to 120 mcg of dietary K1 daily covers baseline coagulation needs; MK-7 supplementation extends coverage to bone and vascular tissue.

Step 3: Recheck at 12 Weeks

PIVKA-II responds to supplementation within weeks. A recheck at 12 weeks gives enough time for tissue saturation to occur. If PIVKA-II remains above 40 mAU/mL despite 200 mcg/day MK-7 and dietary optimization, the workup should shift to ruling out hepatic pathology, including a hepatic function panel and, if indicated, hepatic ultrasound.

Testing Logistics and Ordering Context

PIVKA-II is not included in standard comprehensive metabolic panels. It requires a separate order and is typically processed by specialty reference labs. Serum is stable for 48 hours refrigerated; specimens for PIVKA-II should not be frozen and thawed repeatedly, as this degrades the protein and produces falsely low readings.

Interfering Factors

Several variables confound PIVKA-II interpretation:

• Warfarin and acenocoumarol: Elevates PIVKA-II pharmacologically; results are uninterpretable for nutritional assessment.
• Antibiotics: Broad-spectrum courses suppress gut bacteria that produce menaquinones (MK-4 through MK-13), potentially raising PIVKA-II modestly over 2 to 3 weeks.
• Hemolysis and lipemia: Interfere with immunoassay detection; request a fasting, non-hemolyzed specimen.
• Hepatocellular carcinoma: Tumor cells produce aberrant prothrombin independent of vitamin K status, elevating PIVKA-II even when K stores are replete.

Who Should Be Tested

The American Society for Bone and Mineral Research and guidance documents from the National Institutes of Health Office of Dietary Supplements identify fat malabsorption syndromes, bariatric surgery, and prolonged antibiotic use as conditions warranting monitoring of vitamin K status. Routine population screening with PIVKA-II is not currently recommended by USPSTF or the Endocrine Society. Testing is most productive in:

• Patients with unexplained low bone mineral density on DXA
• Post-bariatric surgery patients at annual metabolic labs
• Patients with chronic fat malabsorption (celiac, Crohn, cholestasis)
• Patients with arterial calcification on imaging without traditional risk factors
• Anyone with a prolonged PT/INR not attributable to warfarin or liver disease

Vitamin K, PIVKA-II, and Cardiovascular Risk

Matrix Gla protein (MGP) is the most potent inhibitor of vascular calcification known in humans. Like prothrombin, MGP requires vitamin K for carboxylation to become active. Uncarboxylated MGP accumulates in arterial walls and fails to prevent calcium phosphate crystal deposition. A landmark observational study, the Rotterdam Study (N=4,807, 10-year follow-up), found that the highest tertile of dietary menaquinone intake was associated with a 41% lower risk of coronary heart disease mortality and a 57% lower risk of aortic calcification compared to the lowest tertile. PIVKA-II was not measured directly in the Rotterdam Study, but the mechanistic pathway runs through the same carboxylation enzyme system.

A subsequent trial, the VitaK-CAC trial published in Atherosclerosis (N=200, 2-year RCT), tested MK-7 360 mcg/day vs placebo in patients with existing coronary artery calcification. MK-7 did not significantly slow CAC progression in the overall group, though subgroup analysis suggested benefit in patients with the highest baseline calcification scores. The cardiovascular evidence base remains promising but not yet sufficient to support a population-wide supplementation recommendation.

Interpreting PIVKA-II in Conjunction with Other Labs

PIVKA-II works best as part of a panel, not in isolation. Useful companion tests include:

• Carboxylated and undercarboxylated osteocalcin ratio: Measures bone-specific vitamin K adequacy directly; a carboxylated fraction below 70% suggests suboptimal bone K status even if PIVKA-II is within range.
• Serum 25-hydroxyvitamin D: Vitamin D and K2 work together on osteocalcin gene expression; deficiency in either blunts the other's effect.
• Serum calcium and magnesium: Required cofactors for Gla-protein function.
• PT/INR: If elevated in a non-anticoagulated patient, PIVKA-II elevation confirms hepatic K deficiency as a contributor; normal PT with elevated PIVKA-II suggests extrahepatic (bone, vascular) deficiency predominates.
• AFP (alpha-fetoprotein): Order alongside PIVKA-II when HCC is in the differential; AFP and PIVKA-II together have higher sensitivity for HCC than either marker alone. A meta-analysis in Hepatology (21 studies, N=3,242) found PIVKA-II sensitivity of 74% and specificity of 87% for HCC; combined AFP plus PIVKA-II sensitivity reached 89%.

Dietary and Supplement Strategies to Optimize PIVKA-II

Reaching and sustaining a PIVKA-II below 20 mAU/mL through diet alone is achievable for most people without malabsorption. Practical approaches include:

• Eating one to two cups of leafy greens daily (kale, spinach, collards each contain 400 to 800 mcg K1 per cooked cup)
• Including fermented soybean products (natto provides 850 to 1,000 mcg MK-7 per 100 g serving, the richest dietary source)
• Using MK-7 supplements 90 to 200 mcg/day when dietary sources are limited
• Taking fat-soluble vitamins with a meal containing at least 10 to 15 g of fat to maximize micellar absorption
• Avoiding prolonged broad-spectrum antibiotics when clinically feasible, or supplementing K2 during and after courses lasting more than 10 days

The NIH Office of Dietary Supplements notes that natto consumption is the primary explanation for why Japanese postmenopausal women historically had lower rates of hip fracture than Western cohorts with similar or lower calcium intakes.

Patients on warfarin should keep vitamin K intake consistent rather than low. Sudden increases in K1 reduce warfarin efficacy; consistent daily intake allows stable INR management. The clinical instruction from current American College of Chest Physicians guidance is to maintain dietary K1, not restrict it, and adjust warfarin dose accordingly.